Omgene Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 23-10-2024
- Paid Up Capital ₹ 2.61 M
as on 23-10-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 71.20 M
as on 23-10-2024
- Satisfied Charges ₹ 93.37 M
as on 23-10-2024
- Revenue 15.18%
(FY 2023)
- Profit 482.15%
(FY 2023)
- Ebitda 67.09%
(FY 2023)
- Net Worth 19.97%
(FY 2023)
- Total Assets 1.75%
(FY 2023)
About Omgene Life Sciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 2.61 M.
The company currently has active open charges totaling ₹7.12 Cr. The company has closed loans amounting to ₹9.34 Cr, as per Ministry of Corporate Affairs (MCA) records.
Udaya Alaparthi and Lakshmiprasad Alaparthi serve as directors at the Company.
- CIN/LLPIN
U24230GJ2011PTC064483
- Company No.
064483
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Omgene Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Udaya Alaparthi  | Director | 17-Mar-2011 | Current |
| Lakshmiprasad Alaparthi | Director | 17-Mar-2011 | Current |
Financial Performance and Corporate Structure Insights of Omgene Life Sciences.
Omgene Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.18% increase. The company also saw a substantial improvement in profitability, with a 482.15% increase in profit. The company's net worth Soared by an impressive increase of 19.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Omgene Life Sciences?
In 2023, Omgene Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 14 Jun 2019 | ₹7.12 Cr | Open |
Others Creation Date: 29 Apr 2022 | ₹3.11 Cr | Satisfied |
Others Creation Date: 29 Apr 2022 | ₹6.23 Cr | Satisfied |
How Many Employees Work at Omgene Life Sciences?
Omgene Life Sciences has a workforce of 80 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Omgene Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Omgene Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
